Jennison Associates
BCRX icon

Jennison Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Jennison Associates’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,100,864
Closed -$25.2M – 648
2019
Q1 		$25.2M Sell
3,100,864
-697,989
-18% -$5.98M 0.03% 323
2018
Q4 		$30.7M Sell
3,798,853
-51,150
-1% -$398K 0.03% 283
2018
Q3 		$29.4M Buy
3,850,003
+378,565
+11% +$2.54M 0.03% 341
2018
Q2 		$19.9M Sell
3,471,438
-33,157
-0.9% -$183K 0.02% 403
2018
Q1 		$16.7M Buy
3,504,595
+422,360
+14% +$2.17M 0.02% 412
2017
Q4 		$15.1M Buy
3,082,235
+5,774
+0.2% +$28K 0.01% 434
2017
Q3 		$16.1M Buy
3,076,461
+995,643
+48% +$5.1M 0.02% 431
2017
Q2 		$11.6M Buy
2,080,818
+236,182
+13% +$1.44M 0.01% 464
2017
Q1 		$15.5M Buy
1,844,636
+489,536
+36% +$3.41M 0.02% 454
2016
Q4 		$8.58M Buy
1,355,100
+3,770
+0.3% +$19.6K 0.01% 489
2016
Q3 		$5.96M Sell
1,351,330
-4,972
-0.4% -$19.9K 0.01% 502
2016
Q2 		$3.85M Sell
1,356,302
-1,302
-0.1% -$4.04K ﹤0.01% 510
2016
Q1 		$3.84M Buy
1,357,604
+9,041
+0.7% +$40.1K ﹤0.01% 501
2015
Q4 		$13.9M Buy
1,348,563
+24,014
+2% +$239K 0.01% 459
2015
Q3 		$15.1M Buy
1,324,549
+6,832
+0.5% +$91.2K 0.02% 468
2015
Q2 		$19.7M Buy
1,317,717
+344,618
+35% +$3.92M 0.02% 460
2015
Q1 		$8.79M Buy
+973,099
New +$10.1M 0.01% 499
2014
Q4 		– Sell
-321,422
Closed -$3.14M – 721
2014
Q3 		$3.14M Buy
321,422
+480
+0.1% +$5.88K ﹤0.01% 544
2014
Q2 		$4.09M Sell
320,942
-37,615
-10% -$366K ﹤0.01% 513
2014
Q1 		$3.79M Buy
358,557
+1,205
+0.3% +$12.8K ﹤0.01% 534
2013
Q4 		$2.72M Sell
357,352
-92,648
-21% -$587K ﹤0.01% 546
2013
Q3 		$3.28M Buy
+450,000
New +$2.28M ﹤0.01% 530

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Jennison Associates's BCRX Position: Q2 2019 in Review

Jennison Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 3,100,864 shares — an estimated $25.2M sold.

Jennison Associates first reported a position in BCRX in Q3 2013 and held it in 22 quarters. The position peaked at $30.7M in Q4 2018. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

  • Jennison Associates reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Jennison Associates sold 3,100,864 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $25.2M.
  • Jennison Associates first reported a position in BioCryst Pharmaceuticals in Q3 2013 and held it in 22 quarters.
  • Jennison Associates's BioCryst Pharmaceuticals position peaked at $30.7M in Q4 2018.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Jennison Associates's 13F filing for Q2 2019, filed 6 Aug 2019.